Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism EBNA1 inhibitors(Epstein-Barr nuclear antigen 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epstein-Barr Virus Infections | Phase 2 | US | - | 04 Apr 2019 |
Nasopharyngeal Neoplasms | Phase 2 | - | - | |
Epstein-Barr virus associated Nasopharyngeal Carcinoma | Phase 1 | FR | - | 04 Apr 2019 |
Epstein-Barr virus associated Nasopharyngeal Carcinoma | Phase 1 | US | - | 04 Apr 2019 |
Epstein-Barr Virus Infections | Phase 1 | FR | - | 04 Apr 2019 |
Nasopharyngeal Carcinoma | Phase 1 | US | Cullinan Pearl Corp.Startup | 11 Mar 2019 |
Epstein-Barr Virus Infections | Preclinical | US | - | 04 Apr 2019 |
Epstein-Barr Virus Infections | Discovery | FR | - | 04 Apr 2019 |
Nasopharyngeal Carcinoma | Discovery | US | Cullinan Pearl Corp.Startup | 11 Mar 2019 |
NCT04925544 (ASCO2023) Manual | Phase 2 | 22 | (rpkyqqyinc) = qsssttszla iwfpzyzruy (qlolegufvn ) View more | Positive | 31 May 2023 |